Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GamaMab's Pockets Replenished: Funds For Gynecological Cancer Trials

This article was originally published in Scrip

Executive Summary

French biotech GamaMabs Pharma has raised €15m in a series B financing round, led by new investor BioDiscovery 4, with hopes to use the money to fund Phase I and Phase II clinical trials of GamaMabs' lead product GM102 (formerly known as 3C23K) for gynecological cancers.